Home › Idiopathic Thrombocytopenic Purpura › Massachusetts
Idiopathic Thrombocytopenic Purpura clinical trials in Massachusetts
6 studies for Idiopathic Thrombocytopenic Purpura are looking for participants at sites in Massachusetts.
Cities in Massachusetts
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Massachusetts General Hospital, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06722235Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 14, 2026 · NCT07095127Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07104565A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Massachusetts General Hospital, Boston
- University of Massachusetts Chan Medical School, Worcester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06948318Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
- Massachusetts General Hospital Cancer Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Mass General Brigham Cancer Institute, Danvers
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jun 22, 2026 · NCT07007962Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
- Massachusetts General Hospital, Boston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 10, 2025 · NCT06817395From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.